|
2023-08-16 |
2023-08-14 |
B
Purchase
|
Anderson Glen R.
Large shareholder
|
23,934
+2.1%
2.34
USD 56,006
|
23,934
+2.1%
|
2.34
|
USD 56,006
|
|
|
2023-08-16 |
2023-08-11 |
B
Purchase
|
Anderson Glen R.
Large shareholder
|
35,064
+3.1%
2.12
USD 74,336
|
35,064
+3.1%
|
2.12
|
USD 74,336
|
|
|
2023-08-16 |
2023-08-10 |
B
Purchase
|
Anderson Glen R.
Large shareholder
|
44,354
+4.1%
1.94
USD 86,047
|
44,354
+4.1%
|
1.94
|
USD 86,047
|
|
|
2022-12-19 |
2022-12-01 |
B
Purchase
|
Litchev Boyan Vesselinov
Chief Medical Officer
Officer
|
500
+76.9%
1.87
USD 935
|
500
+76.9%
|
1.87
|
USD 935
|
|
|
2022-12-19 |
2022-11-22 |
B
Purchase
|
Litchev Boyan Vesselinov
Chief Medical Officer
Officer
|
500
+333.3%
1.83
USD 915
|
500
+333.3%
|
1.83
|
USD 915
|
|
|
2022-11-22 |
2022-11-21 |
B
Purchase
|
Meckler Jeffrey A
CEO and Director
Executive Director
|
9,600
+14.6%
1.90
USD 18,240
|
9,600
+14.6%
|
1.90
|
USD 18,240
|
|
|
2022-11-22 |
2022-11-18 |
B
Purchase
|
Meckler Jeffrey A
CEO and Director
Executive Director
|
400
+0.6%
1.76
USD 705
|
400
+0.6%
|
1.76
|
USD 705
|
|
|
2022-09-12 |
2022-09-08 |
B
Purchase
|
Meckler Jeffrey A
CEO and Director
Executive Director
|
10,308
+18.7%
2.80
USD 28,862
|
10,308
+18.7%
|
2.80
|
USD 28,862
|
|
|
2022-09-09 |
2022-09-07 |
B
Purchase
|
Linscott Walt Addison
Chief Business Officer
Officer
|
150
+inf%
2.62
USD 393
|
150
+inf%
|
2.62
|
USD 393
|
|
|
2022-09-08 |
2022-09-07 |
B
Purchase
|
Meckler Jeffrey A
CEO and Director
Executive Director
|
8,632
+18.6%
2.57
USD 22,184
|
8,632
+18.6%
|
2.57
|
USD 22,184
|
|
|
2022-09-08 |
2022-09-06 |
B
Purchase
|
Meckler Jeffrey A
CEO and Director
Executive Director
|
1,060
+2.3%
2.44
USD 2,586
|
1,060
+2.3%
|
2.44
|
USD 2,586
|
|
|
2022-06-07 |
2022-06-06 |
B
Purchase
|
Meckler Jeffrey A
CEO and Director
Executive Director
|
19,727
+76.9%
2.63
USD 51,882
|
19,727
+76.9%
|
2.63
|
USD 51,882
|
|
|
2022-12-19 |
2022-03-02 |
B
Purchase
|
Litchev Boyan Vesselinov
Chief Medical Officer
Officer
|
50
+50.0%
4.09
USD 205
|
50
+50.0%
|
4.09
|
USD 205
|
|
|
2022-02-02 |
2022-02-01 |
PS
Planned sale
|
Newman Michael James
CSO and Director
Executive Director
Large shareholder
|
14,130
-1.0%
5.00
USD 70,692
|
14,130
-1.0%
|
5.00
|
USD 70,692
|
|
|
2022-12-19 |
2022-01-31 |
B
Purchase
|
Litchev Boyan Vesselinov
Chief Medical Officer
Officer
|
100
+inf%
4.65
USD 465
|
100
+inf%
|
4.65
|
USD 465
|
|
|
2022-02-02 |
2022-01-31 |
PS
Planned sale
|
Newman Michael James
CSO and Director
Executive Director
Large shareholder
|
5,870
-0.4%
5.00
USD 29,351
|
5,870
-0.4%
|
5.00
|
USD 29,351
|
|
|
2021-11-19 |
2021-11-18 |
B
Purchase
|
Meckler Jeffrey A
CEO and Director
Executive Director
|
11,187
+77.4%
5.82
USD 65,108
|
11,187
+77.4%
|
5.82
|
USD 65,108
|
|
